Artios Pharma Strengthens Clinical Development Team with Senior Appointments
CAMBRIDGE, UK and NEW YORK, USA, 10 February 2020 Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the appointment of Bryony Harrop as Vice President (VP) of Clinical Development, Bryony will be working alongside Dr Gillian Langford, also VP of Clinical Development, who joined Artios in January 2019.
Bryony will report directly to Chief Medical Officer, Dr Ian Smith, and in collaboration with Gillian will be responsible for the clinical development strategy, regulatory, and medical activities of Artios’ medicines that target aspects of DNA Damage Response (DDR), including inhibitors of DNA Polymerase Theta and Ataxia-Telangiectasia and Rad3 – related protein kinase (ATR) programmes.
Commenting on the appointments, Chief Medical Officer, Dr Ian Smith added: “On behalf of the executive team I am pleased to welcome Bryony to Artios, to work with Gillian and myself at this exciting time for the company. Following the recent acquisition of the small-molecule ATR inhibitor programme, Gillian’s extensive expertise in the drug development process along with Bryony’s experience and in-depth knowledge of clinical development will be invaluable as we advance our clinical programmes, bringing next-generation DNA Damage Response (DDR) therapies to cancer patients.”
Bryony is a seasoned pharmaceutical industry professional with extensive experience through all stages of drug development in cutting-edge oncology clinical trials across a broad range of malignancies. She was previously Oncology Delivery Director at AstraZeneca where over a period of fifteen years she held various leadership positions in the Early Clinical Development and Global Medical Affairs units. Before AstraZeneca, Bryony worked at contract research organisations such as MDS Harris and Chiltern International Limited and in the NHS at Northampton Community Healthcare Trust. Bryony holds a B.Sc. in Biochemistry and Biological Chemistry from the University of Nottingham.
Bryony will be working closely with Gillian who has over 25 years’ research and development experience in both pharmaceutical and biotechnology companies. Gillian joined Artios from Bicycle Therapeutics where she was part of the leadership team and was VP of Clinical and Project Management and responsible for moving Bicycle’s lead compound into the clinic. Prior to joining Bicycle, Gillian was Director of Programme Management at Boyd Consultants and worked with European and North American companies developing oncology products and gene-based medicines. Gillian graduated from Imperial College London and obtained her Ph.D. in molecular biology at York University.
For more information, please contact:
Artios Pharma Ltd.
Niall Martin, Chief Executive Officer
Tel: +44 (0)1223 804180
Media & IR Enquiries
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Tel: +44 (0) 203 950 9144
Notes to Editors
About Artios Pharma Limited
Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company, founded by SV Health Investors in 2016, is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and the National Centre for Biomolecular Research at Masaryk University in the Czech Republic. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers. Backed by blue chip investors including: Arix Bioscience plc, SV Health Investors, M Ventures, IP Group plc, AbbVie Ventures, Andera Partners (formerly EdRIP), LSP, Pfizer Ventures and Novartis Venture Fund (NVF). Artios is based at the Babraham Research Campus in Cambridge, UK, with offices in New York City, USA.